![deucravacitinib](https://www.adcreviews.com/wp-content/uploads/2022/09/deucravacitinib-300x156.jpg)
FDA approves deucravacitinib for plaque psoriasis
On September 10, Bristol-Myers Squibb (BMS) announced that the marketing application of its TYK2 inhibitor deucravacitinib for the treatment of plaque psoriasis has been approved
On September 10, Bristol-Myers Squibb (BMS) announced that the marketing application of its TYK2 inhibitor deucravacitinib for the treatment of plaque psoriasis has been approved